TORONTO, ON — August 8, 2025 — Leads & Copy — Quantum BioPharma Ltd. (NASDAQ: QNTM) announced that a Positron Emission Tomography (PET) tracer used in a joint study with Massachusetts General Hospital (MGH) scientists shows the ability to capture differences across lesions in multiple sclerosis (MS) patients. According to the company, this may prove highly useful for monitoring myelin integrity and demyelination in MS.
The study by Drs. Pedro Brugarolas and Eric Klawiter of MGH, published in the European Journal of Nuclear Medicine and Molecular Imaging, evaluated the PET tracer [18F]3F4AP in healthy controls and in people with MS. The tracer was developed by Dr. Pedro Brugarolas, an investigator in the Department of Radiology at MGH and Assistant Professor at Harvard Medical School, and the study was funded by the National Institutes of Health (NIH).
The study found that [18F]3F4AP has properties for imaging the human brain and was able to detect differences across lesions not visible by conventional MRI. Quantum Biopharma believes that the tracer holds potential as a biomarker to monitor changes in demyelination in MS, and myelin changes in response to Quantum Biopharma’s neuroprotective drug, Lucid-21-302.
Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma, said that the published study shows that the PET tracer is promising as a biomarker to detect and monitor lesions in people with MS and that the ongoing collaborative study with MGH seeks to evaluate the imaging agent and its potential to demonstrate the effectiveness of drugs, such as Lucid-21-302 (Lucid-MS) that can protect the myelin sheath in MS.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board, can be reached at Zsaeed@quantumbiopharma.com or (833) 571-1811.
Source: Quantum BioPharma
